# Chinese guidelines on the treatment of hemophilia（2025）

## TL;DR

This paper presents updated Chinese guidelines for treating hemophilia, a genetic bleeding disorder, focusing on new therapies like long-acting clotting factors and gene therapy.

## Contribution

The paper introduces the first Chinese guidelines for hemophilia treatment in 2025, incorporating novel therapies and standardized practices.

## Key findings

- Hemophilia A accounts for about 80% of all hemophilia cases due to FⅧ deficiency.
- New treatments, including long-acting clotting factors and gene therapy, have improved patient outcomes in China.
- The guidelines aim to standardize treatment approaches with the latest medical advancements.

## Abstract

血友病是一种Ⅹ染色体连锁的隐性遗传性出血性疾病，主要由凝血因子Ⅷ（FⅧ）或凝血因子Ⅸ（FⅨ）活性降低或缺乏所致。根据缺乏的凝血因子不同，可分为血友病A（FⅧ缺乏）和血友病B（FⅨ缺乏）两类，分别由相应凝血因子基因突变引起，其中血友病A最常见，约占血友病总数的80%。近年来，随着长效凝血因子产品、非因子类产品及基因治疗等治疗手段的问世，血友病已进入新型治疗时代，部分产品已在我国上市，显著改善了患者的治疗效果。为规范新型治疗方式及治疗理念下的诊疗行为，中华医学会血液学分会血栓与止血学组与中国血友病协作组共同制定了本指南。